Membership

The Working Group is a pathology-driven group of experts, assisted by experts clinicians, scientist and statisticians. The Working Group is open to open to include all pathologists willing to get involved in the activities of the group.

Please send an email to roberto@salgado.be

Information on Membership

    1. Membership of the Working Group is on a voluntary basis.
    2. All members will receive 2-3 times a year a mailing from the chair of the WG with the details of the ongoing projects so that all remain informed.
    3. This communication is done by e-mail and a copy of this mailing is posted on the BLOG of the TIL-website, under the item “Practical Info for all members”.
    4. In order to achieve uniformity in the methodology of scoring TILs worldwide, each member is encouraged to use the Internationally accepted guideline and do their part for promotion and dissemination of the guideline.

The following is a list of current members of the International Immuno-Oncology Working Group (TILs Working Group)*. A member is defined as a person willing to be involved, informed and be part of the activities of the TILs Working Group. The authors alone are responsible for the views expressed in the work of the TILs Working Group and they do not necessarily represent the decisions, policy or views of their employer.

  1. Roberto Salgado, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium (Co-Chair, Founder, Core-Group Member)
  2. Sherene Loi, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia (Co-Chair, Founder, Core-Group Member)
  3. Carsten Denkert, University of Marburg, Marburg, Germany (Co-Chair, Founder, Core-Group Member)
  4. Sunil Badve, Department of Pathology, Indiana University, Indianapolis, USA (Founder, Core-Group Member)
  5. Sandra Demaria, Department of Pathology, Weill-Cornell Medicine, New York, USA (Founder, Core-Group Member)
  6. Sylvia Adams, Perlmutter Cancer Center, New York University Medical School, New York, USA (Founder, Core-Group Member)
  7. Stefan Michiels, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Université Paris-Sud, Institut National de la Santé et de la Recherche Médicale, Villejuif, France (Founder, Core-Group Member)
  8. David Rimm, Department of Pathology, Yale University School of Medicine, New Haven, USA (Core-Group Member)
  9. Fraser Symmans, Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, USA (Core-Group Member)
  10. Stephen Hewitt, Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA (Core-Group Member)
  11. John Bartlett, Ontario Institute for Cancer Research, Toronto, Canada; IGGM Edinburgh, UK (Core-Group Member)
  12. Torsten Nielsen, Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada (Core-Group Member)
  13. Christos Sotiriou, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium (Core-Group Member)
  14. Giuseppe Viale, Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy (Core-Group Member)
  15. Giancarlo Pruneri, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico–Isituto Nazionale dei Tumori, Universita degli Studi di Milano, Milan, Italy (Core-Group Member)
  16. Sybille Loibl, dlw Laborsoftware UG (haftungsbeschränkt) Lübben, Germany (Core-Group Member)
  17. Abaete Canto, Surgical Pathology, SBP
  18. Aicha Ben Taieb, Roche
  19. Aini Hyytiäinen, Department of Oral and Maxillofacial Diseases, Helsinki, Finland
  20. Akira I. Hida, Department of Pathology, Matsuyama Shimin Hospital, Ehime, Japan
  21. Akli Hanane – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  22. Alastair Thompson, Surgical Oncology, Baylor College of Medicine, Texas, USA
  23. Albrecht Stenzinger, Institute of Pathology Heidelberg (IPH), University Hospital Heidelberg, Heidelberg, Germany
  24. Alejandra Wernicke, Anatomical Pathology, Hospital Italiano de Buenos Aires, Argentina
  25. Alejandro Rojo-Sebastian – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  26. Aleksei Konstantinov, Department of Pathology, Saint-Petersburg clinical scientific and practical center for specialised types of medical care (oncological), St.Petersburg, Russia.
  27. Ales Ales, The Fingerland Department of Pathology, University Hospital Hradec Kralove, Czech Republic
  28. Alex Lefevre, Roche Diagnostics, Belgium
  29. Alex Decaluwe, Department of Radiology, Jules Bordet Institute, Belgium
  30. Alexander Emelyanov – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  31. Alexander Makanga, Histopathology Department, Betsi Cadwaladr University Health Board, United Kingdom
  32. Alexander J. Lazar, Departments of Pathology, Genomic Medicine, Dermatology, and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  33. Alfredo Butera – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org               
  34. Alicia Iturriagagoitia – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  35. Allen Gown, PhenoPath Laboratories, Seattle, USA
  36. Amanda Lowe, Visiopharm
  37. Amine Kallala, Hopitalle Charles Nicolle, Tunisia
  38. Amy Lo, Research Pathology, Genentech Inc., South San Francisco, USA        
  39. An Coosemans, Oncology, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Belgium
  40. Ana Calatrava, Fundacion Intituto Valenciano de Oncologia, Valencia, Spain
  41. Ana Godoy – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  42. Ana Ramirez – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  43. Ana C. Garrido Castro, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  44. Anant Madabhushi, Case Western Reserve University; Louis Stokes Cleveland Veterans Health Administration Medical Center, Ohio, USA
  45. Anders Dahlstrand – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  46. Andre Moreira, Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University, New York, New York, USA
  47. Andrea Richardson, Department of Pathology, Johns Hopkins Hospital, Baltimore, USA
  48. Andrea Vingiani, Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy
  49. Andreas Koulovasilopoulos – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org United Kingdom
  50. Andrew Tutt, Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom
  51. Andrew H. Beck, PathAI, Inc., Cambridge, USA
  52. Andrew M. Bellizzi, Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, USA
  53. Angel Guerrero, Department of Oncology, IVO Valencia, Spain
  54. Angela Quintana, Vall d’Hebrón Hospital Research Institute, Autoimmune Diseases department, Barcelona, Spain
  55. Angela Thiel – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org               
  56. Aniko Kovacs – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  57. Anita Cassiano – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  58. Anita Grigoriadis , Cancer Bioinformatics Lab, Cancer Centre at Guy’s Hospital, London, UK; School of Life Sciences and Medicine, King’s College London, London, United Kingdom
  59. Anna Ehinger, Department of Clinical Genetics and Pathology, Skåne University Hospital, Lund University, Lund, Sweden
  60. Anna Sapino, University of Turin / Candiolo Cancer Institute – FPO, IRCCS, Candiolo, Italy 
  61. Anne Martel, Medical Biophysics, University of Toronto, Toronto, Canada
  62. Anne Vincent-Salomon, Institut Curie, Department of Pathology, Inserm U934,Paris Sciences Lettres University, Paris, France
  63. Anne-Vibeke Laenkholm, Department of Surgical Pathology Zealand University Hospital, Demark
  64. Anthony Gill, University of Sydney, Sydney, Australia
  65. Antonio Wolff, Breast Cancer Trials, Women’s Malignancies Disease Group, The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA
  66. Aparna Harbhajanka, Department of Pathology, University Hospitals Cleveland Medical Center affiliated  with Case Western University, Ohio, USA
  67. Arif Jahangir, Cancer Biology and Therapeutics Laboratory, School of Biomolecular and Biomedical Science, UCD Conway Institute, Dublin, Ireland
  68. Arman Rahman, Precision Oncology Ireland, Conway Institute, UCD Ireland
  69. Arthur Schreurs, Public Health and Primary Care, Katholieke Universiteit Leuven, Belgium
  70. Ashish Sharma, Department of Biomedical Informatics, Emory University, GA, USA
  71. Ashley Cimino-Mathews, Departments of Pathology and Oncology, The Johns Hopkins Hospital, Baltimore, USA               
  72. Ashok Srinivasan , National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, Pennsylvania, USA
  73. Asokan Paupathy, Department of Pathology, NSW Health Pathology, NSW Australia
  74. Bai Baibai – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  75. Balazs Acs, Department of Pathology, Karolinska Institute, Sweden
  76. Baljit Singh, Department of Pathology, New York University Langone Medical Centre, New York, USA
  77. Beatriz Lopez – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  78. Belma Dogdas – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  79. Benjamin Calhoun, Department of Pathology and Laboratory Medicine, UNC School of Medicine, USA
  80. Benjamin Haibe-Kans, Bioinformatics and Computational Genomics Laboratory, Princess Margaret Cancer Center, Toronto, Canada
  81. Benjamin Solomon, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
  82. Bernadette McLaren – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  83. Bernardo L Rapoport, The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
  84. Bibhusal Thapa, Department of Medicine, University of Melbourne, Parkville, Australia
  85. Xiaoxian (Bill) Li, Emory University, USA
  86. Brad H. Nelson, Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada
  87. Brandon Gallas, Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
  88. Carla Valenti – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  89. Carlos Dos Anjo, Merck
  90. Carlos Castaneda, Department of Research, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
  91. CarmenBallesteros-Merino, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute/Providence Cancer Center, Portland, Oregon, USA
  92. Carmen Criscitiello, Department of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy
  93. Carolien Boeckx, Roche Diagnostics, Belgium
  94. Carolien van Deurzen, Department of Pathology, Erasmus MC, Cancer Institute, Rotterdam, The Netherlands
  95. Caroline Carey,  Roche Diagnostics, Belgium
  96. Caterina Marchio, University of Turin at Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy 
  97. Cecile Colpaert, Department of Pathology, AZ Turnhout, Turnhout, Belgium
  98. Cecily Quinn, Department of Pathology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland
  99. Chakra S. Chennubhotla,  Department of Computational and Systems Biology, University of Pittsburgh, USA    
  100. Chanel Smart –  To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org               
  101. Charles Parker, UCL Cancer Institute, United Kingdom
  102. Charles Swanton, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, United Kingdom
  103. Cian Martyn – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  104. Cinzia Solinas, Azienda AUSL, Regional Hospital of Aosta, Aosta, Italy
  105. Clare Yu, Department of Physics and Astronomy, University of California, Irvine, Irvine, CA, USA
  106. Crispin Hiley, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, United Kingdom
  107. Cynthia Chauhan, Mayo Clinic Breast SPORE, Mayo Clinic, Rochester, MN, USA
  108. Damien Drubay, Gustave Roussy, Universite Paris-Saclay, Villejuif, France; Université Paris-Sud, Institut National de la Santé et de la Recherche Médicale, Villejuif, France
  109. Damilys Joelly Santos – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  110. Daniel Bethmann, University Hospital Halle (Saale), Institute of Pathology, Halle (Saale), Germany    
  111. Daniel Stover, Ohio State University Comprehensive Cancer Center, Ohio, USA        
  112. Daniel Sur, Department of Medical Oncology, University of Medicine “I. Hatieganu” Cluj Napoca, Romania    
  113. Danny Jang – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org               
  114. David Clunie, Consulting, PixelMed, Pennsylvenia, USA
  115. David Williams, Anatomical Pathology, Austin Health, Heidelberg, Australia
  116. David A. Moore, Department of Pathology, UCL Cancer Institute, UCL, London, UK; University College Hospitals NHS Trust, London, United Kingdom
  117. Deborah A. Dillon, Department of Pathology, Brigham and Women’s Hospital, Boston, MA Department of Pathology, Dana Farber Cancer Institute, Boston, MA, USA
  118. Denis Larsimont, Department of Pathology, Jules Bordet Institute, Brussels, Belgium
  119. Dhanusha Sabanathan, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia
  120. Diana Ruiz – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  121. Dieter Peeters,  HistoGeneX NV, Antwerp, Belgium and AZ Sint-Maarten Hospital, Mechelen, Belgium
  122. Dimitrios Zardavas, Oncology Clinical Development, Bristol-Myers Squibb, Princeton, USA
  123. Dongyan Liu – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  124. Dora Sabino – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  125. Doris Hoeflmayer, Institut für Pathologie , UK Hamburg, Germany
  126. Douglas B. Johnson, Department of Medicine, Vanderbilt University Medical Centre, Nashville, USA
  127. Duilio Della Libera – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  128. Aubrey Thompson, Department of Cancer Biology, Mayo Clinic, Jacksonville, USA
  129. Edgardo Parrilla Castellar, Q2 Solutions, USA
  130. Edi Brogi, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  131. Edith Perez, Department of Oncology, Mayo Clinic, Rochester, USA
  132. Eduardo Rrichardet, Instituto Oncológico Córdoba, Spain
  133. Ehab ElGabry, Roche, Tucson, USA
  134. Eiichi Konishi, Departments of Surgical Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  135. Eiji Suzuki, Kyoto University, Department of Breast Surgery, Kyoto, Japan.
  136. El Attar Hicham  Biohisto Group, Annasr Pathology Center, Jedida, Morroco                 Morocco
  137. Eldad Klaiman, Roche
  138. Elena Provenzano, Department of histopathology, Addenbrookes Hospital, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom
  139. Elisabeth Ida Specht Stovgaard, Department of Pathology, Herlev and Gentofte University Hospital, Herlev, Denmark
  140. Elizabeth F. Blackley, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
  141. Elżbieta Senkus-Konefka, Department of Oncology & Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
  142. Elton Rexhepaj, Research & Development, Sanofi
  143. Elvire Roblin, Université Paris-Saclay, Univ. Paris-Sud, Villejuif, France; and Service de biostatistique et d’épidémiologie, Gustave Roussy, Villejuif, France
  144. Emad Shash, Breast Cancer Comprehensive Center, National Cancer Institute, Cairo University, Cairo, Egypt
  145. Emarene Kalaw – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  146. Emiel Janssen, Department of Pathology, Stavanger University Hospital, Norway; Griffith University, Australia
  147. Emilio Bria, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
  148. Emily Reisenbichler, Department of Pathology, Yale School of Medicine, New Haven, USA
  149. Emma Colliver – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  150. Enrico Orvieto, UOC Anatomia Patologica, ULSS5 Polesana Rovigo, Italy
  151. Enrique Bellolio, Department of Anatomic Pathology, Faculty of Medicine, Universidad De La Frontera, Temuco Chile     
  152. Erich Huang, National Cancer Institute, Maryland, USA
  153. Eslie Dennis, Ventana
  154. Eudald Felip, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
  155. Eunice Spengler, Departmento de Patologia, Hospital Universitario Austral, Argentina.
  156. Eva Balslev, Department of Pathology, Herlev and Gentofte Hospital, Denmark
  157. Ewa Chmielik, Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland
  158. Ewan Millar, NSW Health Pathology, St George Hospital, Sydney, Australia
  159. Fabien Gaire, Pathology and Tissue Analytics, Roche
  160. Fabrice Andre, Department of Medical Oncology, Gustave Roussy, Villejuif, France
  161. Fang Fan, Department of Pathology, University of Kansas Medical Center, USA
  162. Fang-I Lu, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Canada
  163. Farid Azmoudeh-Ardalan, Tehran University of Medical Sciences, Iran
  164. Fatima Cardoso, Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
  165. FayÇõal Abbad – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  166. Federica Miglietta, Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy
  167. Federico Rojo, Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain; GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain
  168. Felicia Leion – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  169. Felip Garcia, Pathology Department, Hospital Quiron Salud Spain
  170. Filipp Ofra – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  171. Filomena Carvalho – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  172. Fiorela Mego Ramirez –  To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  173. Fiorita Mundim – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  174. Francesco Ciompi, Computational Pathology Group, Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
  175. Franciszek Binczyk – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  176. Franklin Peale, Oncology Biomarker Development, Genentech-Roche
  177. Franklin Sedarat, Q2 Solutions, USA
  178. Franz Burger – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  179. Fred R. Hirsch,    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
  180. Frederick Klaushen, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany
  181. Frederique Penault-Llorca, Centre de Lutte Contre le cancer – Centre Jean Perrin, Clermont-Ferrand, France
  182. Gabor Cserni, Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; Department of Pathology, University of Szeged, Szeged, Hungary.
  183. Gabriela Acosta-Haab, Department of Pathology, Hospital de Oncología Maria Curie, Buenos Aires, Argentina
  184. Gabriela IzabelaBaltatescu – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  185. Galina Khramtsova – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  186. Gavin Harris, Canterbury Health Laboratories, New Zealand
  187. Gazzi Carla – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  188. GǬlcihan Eker – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  189. Gediminas Smailys – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  190. Gelareh Farshid, Directorate of Surgical Pathology, SA Pathology, Adelaide, Australia
  191. George Kumar,  Bristol Myers Squibb, USA
  192. Gert Van den Eynden, Department of Pathology, GZA-ZNA Ziekenhuizen, Wilrijk, Belgium
  193. Giampaolo Bianchini, Medical Oncology, San Raffael Scientific Institute, Italy
  194. Giampaolo Tortora – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  195. Giovanna Garufi, Medical Oncology Unit, Agistino Gemelli IRCCS Polyclinic Foundation, Rome, Italy.
  196. Giuseppe Floris, KU Leuven- Univerisity of Leuven, Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research and KU Leuven- University Hospitals Leuven, Department of Pathology, Leuven, Belgium Belgium
  197. Giuseppe Curigliano, University of Milano, Istituto Europeo di Oncologia, IRCCS, Milano, Italy
  198. Gizem Oner, Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital Belgium
  199. Glenn Broeckx, Department of Pathology, University Hospital Antwerp, Belgium    
  200. Gloria Inurrigarro – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  201. Gun Min Kim – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  202. Guray Akturk, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  203. Gwen Dackus – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org Netherlands
  204. Hannah Wen, Memorial Sloan Kettering Cancer Centre, USA
  205. Harmut Koeppen, Research Pathology, Genentech Inc., South San Francisco, USA
  206. Harry Haynes, Translational Health Sciences, Department of Cellular Pathology, North Bristol NHS Trust, University of Bristol, United Kingdom
  207. Heather McArthur, Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
  208. Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland
  209. Helena Olofsson, Department of Clinical Pathology, Akademiska University Hospital, Uppsala, Sweden               
  210. Hernan Garcia Rivello, Anatomical Pathology, Hospital Italiano de Buenos Aires, Argentina.  
  211. Hirofumi Matsumoto, Department of Pathology, Nakagami Hospital, Okinawa, Japan
  212. Houssein Sater – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  213. Huang-Chun Lien, Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan
  214. Hugo M. Horlings, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  215. Hyun Joo Choi, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, South Korea
  216. Ian Cree, International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France
  217. I-Chun Chen, Department of Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
  218. Ida Pavon, Ulss 3, Italy
  219. Ignasi Roig I Quilis, Departmento de Anatomia Patologica, Hospital de Terrassa, Barcelona, Spain
  220. Ilaria Porcellato, Department of Veterinary Medicine, University of Perugia, Italy
  221. Indu Arun, Department of Histopathology, Tata Medical Center, Kolkata, Indi
  222. Inna Ganshina – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  223. Inne Nauwelaers, Public Health and Primary Care, KU Leuven, Belgium
  224. Inta Liepniece- Karele – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  225. Ioannis Roxanis, Institute of Cancer Research, United Kingdom
  226. Ipek Coban, Anatomic Pathology, Istanbul Florence Nightingale Hospital, Turkey
  227. Iris Nederlof, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  228. Isaac Garcia-Murillas, Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom
  229. Isabel Amendoeira, Serviço de Anatomia Patológica, Centro Hospitalar Universitario de São João and Ipatimup, Porto, Portugal
  230. Isabel Frahm, Department of Pathology, Sanatorio Mater Dei, Buenos Aires, Argentina
  231. Isabella Castellano, Department of Medical Sciences, University of Turin, Italy
  232. Iva Brcic, Institute of Pathology, Medical University of Graz, Austria
  233. Jacinta Fong, Harry Perkins Institute of Medical Research, University of Western Australia
  234. Jack Chan, Department of Oncology, National Cancer Centre, Singapore
  235. Jacqueline A. Hall, Vivactiv Ltd, Bellingdon, Bucks, United Kingdom
  236. James Ziai, Research Pathology, Genentech Inc., South San Francisco, USA
  237. Jan Hudeek, Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  238. Jane Brock, Department of Pathology, Brigham and Women’s Hospital, Boston, USA
  239. Janina Kulka, Department of Pathology, Semmelweis University, Budapest, Hungary
  240. Javier Cortes, Head breast Cancer Program, Oncology Department, IOB institute of Oncology, Quiron Group, Spain
  241. Jean-Christophe Tille, Department of Pathology, University Hospital, Geneva, Switzerland
  242. Jeffrey Fine – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  243. Jeffrey Shear, Information Technology, Wiss & Company, LLP, J Shear Consulting, LLC, New York, USA               
  244. Jelle Wesseling,  Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands               
  245. Jennifer Giltnane, Research Pathology, Genentech Inc., South San Francisco, USA
  246. Jennifer Kerner, PathAI Inc., Cambridge, USA          
  247. Jeppe Thagaard, DTU Compute, Department of Applied Mathematics, Technical University of Denmark; Visiopharm A/S, Denmark
  248. Jeremy Braybrooke, Nuffield Department of Population Health, University of Oxford, Oxford and Department of Medical Oncology, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
  249. Jeremy Thomas, Q2 Solutions, USA
  250. Jeroen Van der Laak, Computational Pathology Group, Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
  251. Jerome Lemonnier, R&D UNICANCER, Paris, France
  252. Jiping Zha, Translational Sciences, MedImmune, Gaithersberg, USA
  253. Joana Ribeiro, Breast Unit, Champalimaud Clinical Centre, Lisboa, Portugal
  254. Jochen K. Lennerz, Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
  255. Jodi M. Carter, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA
  256. Joel Saltz, Department of Biomedical Informatics and Department of Pathology, Stony Brook School of Medicine, Stony Brook, USA
  257. Joël Cucherousset, GHI Le Raincy-Montfermeil, Chelles, Île-de-France, France
  258. Johan Hartman, Deptartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
  259. Johan Lundin, Institute for Molecular Medicine Finland, University of Helsinki, Finland
  260. John Cochran, Q2 Solutions, Atlanta, GA, USA
  261. John Le Quesne, Leicester Cancer Research Centre, University of Leicester, Leicester, and MRC Toxicology Unit, University of Cambridge, United Kingdom
  262. Jonathan Klein, Albert Einstein College of Medicine in New York, USA
  263. Jonathon W. Juco, Merck & Co., Inc., Kenilworth, USA
  264. Jorge Reis-Filho, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  265. Jorge Adriano Ferreira Pinheiro – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  266. Jose van den Berg, Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  267. Jose Fernando do prado Moura, Centro de Pesquisas Clinicas do IMIP, Brasil
  268. Jose Ignacio Chacan – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  269. Jose Luis Solorzano Rendon, Pathology and Molecular Diagnostics department, MD Anderson Cancer Center Madrid, Spain
  270. Josefine Sandstrom, Linköping University, Sweden
  271. Joselyn Sanchez, Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
  272. Joseph Anderson – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  273. Joseph Sparano, Department of Medicine, Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein Medical Center, Bronx, USA
  274. Juan Carlos Araya, Department of Pathology, Universidad de La Frontera, Temuco, Chile
  275. Julian Iturbe – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  276. Juliana Freitas, Pathology Department, Federal University of Bahia, Brazil
  277. Julien Adam, Department of Pathology, Gustave Roussy, Grand Paris, France
  278. Junjeong Choi – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  279. Junzo Kawaguchi – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  280. Justin M. Balko, Departments of Medicine and Cancer Biology, Vanderbilt University Medical Centre, Nashville, USA
  281. Kai Saeger,  Vm Scope, Germany
  282. Kareem Hosny, Department of Pathology, University of Pennsylvania, USA
  283. Karen Willard-Gallo, Molecular Immunology Unit, Institut Jules Bordet, Brussels, Belgium
  284. Karsten Weber, German Breast Group, Neu-Isenburg, Germany
  285. Karthickbalan Subramanian – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  286. Katey Enfield – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  287. Katherine Elfer, Division of Imaging, Diagnostics, and Software Reliability, US Food and Drug Administration, Silver Spring, MD, USA
  288. Katherine Pogue-Geile, NSABP/NRG Oncology, Pittsburgh, PA, USA
  289. KatsuhiroYoshikawa, Kansai Medical University Medical Center, Osaka, Japan
  290. Keith E. Steele, Translational Sciences, MedImmune, Gaithersberg, USA
  291. Kenneth Emancipator, Merck & Co., Inc., Kenilworth, USA
  292. Kevin Thia – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  293. Khalid El Bairi, Cancer Biomarkers Working Group, Oujda, Morocco
  294. Khalid Abdul Jabbar, Centre for Evolution and Cancer; Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
  295. Kim R.M. Blenman, Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University, School of Medicine, New Haven,  CT , USA
  296. Kimberly H. Allison, Pathology Department, Stanford University Medical Centre, Stanford, USA
  297. Koen K. van de Vijver, Department of Pathology, University Hospital Ghent, Belgium
  298. Konstanty (Popi) Korski, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
  299. Kosuke Kawaguchi, Department of Breast Surgery, Kyoto University, Kyoto, Japan.
  300. Kristin Galas – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  301. Lajos Pusztai, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale School of Medicine, New Haven, CT , USA
  302. Larissa Mendes, Oncology Department, Cancer Institute, University College London, London,                United Kingdom
  303. Laura Comerma, Pathology Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain; GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain
  304. Laura Yee, National Cancer Institute, Maryland, USA
  305. Laurence Buisseret, Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  306. Lax Sigurd, Department of Pathology, Hospital Graz II, Academic Teaching Hospital of the Medical University Graz, Austria
  307. Lee Cooper, Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
  308. Leming Shi, Center for Pharmacogenomics and Fudan-Zhangjiang, Center for Clinical Genomics School of Life Sciences and Shanghai Cancer Center, Fudan University, China
  309. Leonie Voorwerk, Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  310. Leslie Cerpa – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  311. Leslie Gilham, Consumer Advisory Panel, Breast Cancer Trials, Australia
  312. Lingyu Li, School of Control Science and Engineering, Shandong University, China
  313. Lisa McShane, Cancer Therapy Evaluation Program, National Cancer Institute, Maryland, USA
  314. Liudmila Beziaeva – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  315. Loes Kooreman, Department of pathology, Maastricht University Medical Centre, Maastricht, The Netherlands
  316. LorenzoGianni -To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  317. Lounis Khaled – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  318. LubomirBodnar – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  319. Luc Dirix, Medical Oncology, GZA, Antwerp, Belgium
  320. Luciana Fujimoto, Pathology and Legal Medicine, Amazon Federal University, Brasil
  321. Luciana Molinero, Oncology Biomarker Development, Genentech-Roche
  322. Luis Claudio, Amendola Brazilian Socity of Oncology, Brazil
  323. Luisa Paola, Molteni – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  324. Luz Sua, Department of Pathology, Fundación Valle del Lili, Cali, Colombia
  325. Valeria Estrada, Biorepository and Tissue Technology Shared Resources, University of California San Diego, USA
  326. Maartje van Seijen, Department of molecular pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
  327. Magali Lacroix-Triki, Department of Pathology, Gustave Roussy, Villejuif, France
  328. Maggie Cheang,  Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, United Kingdom
  329. Mahasti Saghatchian, Pathology, Institute Gustave Roussy, France
  330. Maise al Bakir, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, United Kingdom
  331. Mako Nogami – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  332. Manish Manu Subramaniam, Anatomic Pathology, Q2 Lab Solutions, United Kingdom
  333. Manu Sebastian, Departments of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  334. Maria Cebollero, Pathology Department. Hospital General Universitario Gregorio Marañón. Madrid, Spain.    
  335. Marcelo Balancin, Department of Pathology, Faculty of Medicine, University of São Paulo; São Paulo, Brazil
  336. Marcelo Souto Maior, Pathology, Federal University of Pernambuco, Brazil
  337. Maria Alice Franzoi – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  338. Maria Pia Foschini – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  339. Maria Teresa Ramieri – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  340. Maria Vittoria Dieci – Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
  341. Marie-Christine Mathieu – Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France
  342. Mariia Urezkova- To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  343. Marilyn Bui – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  344. Marjan Hertoghs, Pathology department of ZNA and GZA hospitals in Antwerp, Belgium
  345. Mark O’Loughlin- To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  346. Mark Robson, Memorial Sloan Kettering Cancer Center, NY, US
  347. Mark Webber – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  348. Mark van de Vijver, Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands
  349. Markus Herrmann – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org USA
  350. Marleen Kok, Divisions of Medical Oncology, Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  351. Marlon C. Rebelatto, Translational Sciences, MedImmune, Gaithersberg, USA
  352. Martine Piccart, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
  353. Martino Bosco, Pathology, ASLCN2, Italy
  354. Mary Schneck, Histogenex
  355. Masahiro Takada, Kyoto University, Department of Breast Surgery, Kyoto, Japan.
  356. Masakazu Toi, Department of Breast Surgery, Kyoto University, Kyoto, Japan.
  357. Masoumeh, Gharib, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  358. Matt Leavitt – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  359. Matthew G. Hanna, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  360. Matthew P. Goetz, Department of Oncology, Mayo Clinic, Rochester, USA
  361. Matthias Preusser, Department of Medicine, Clinical Division of Oncology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria
  362. Mehrnoush Khojasteh, Roche Tissue Diagnostics, Digital Pathology, Santa Clara, CA, USA
  363. Melinda E. Sanders, Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Centre, Nashville, USA
  364. Melisa Vazquez – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  365. Meredith M. Regan, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA
  366. Michael Firer, Adelson School of Medicine, Ariel University, Israel
  367. Michael Barnes,Digital Pathology, Personalized Healthcare Group in Product Development, Genentech, USA
  368. Michael Christie, Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Australia
  369. Michael DiMaio, Pathology, DPMG, USA
  370. Michael Misialek , Vernon Cancer Center, Newton-Wellesley Hospital, Newton, USA
  371. Michail Sofopoulos, Department of Surgical Pathology, “Saint Savvas” Regional Anticancer Hospital, Athens Greece
  372. Michail Ignatiadis, Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  373. Michiel de Maaker, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  374. Mieke Van Bockstal, Service de pathologique, Cliniques universitaires Saint-Luc, Bruxelles, Belgium
  375. MiglenaKomforti – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  376. Miluska Castillo, Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru
  377. Minetta Liu, Mayo Clinic, Rochester, Minnesota Joint Appointment, Department of laboratory Medicine and Pathology, Research Chair, Division of Medical Oncology, USA
  378. Mitsuaki Ishida, Department of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan
  379. Mohamed Zaakouk – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  380. Mohamed Amgad, Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA
  381. Mohamed Amgad Tageldin, Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA
  382. Molly Klein, Department of Laboratory Medicine and Pathology, University of Minnesota, USA
  383. Monica Modesto Araujo e Porfirio, Department of Pathology, Argos – Fortaleza-CE, Brazil
  384. Montse Velasco, Department of Oncology, Hospital de Mataro, Bercelona, Spain
  385. Morven Hollick, School of Medicine, Medical Science and Nutrition, University of Aberdeen, Scotland
  386. Nadia Villena – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  387. Nadia Harbeck, Breast Center, Dept. OB&GYN and CCC (LMU), University of Munich, Munich, Germany
  388. Nadine Tung,  Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, USA
  389. Naila Bacha – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  390. Najat Bouchmaa, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, Beni Mellal, Morocco
  391. Navita Somaiah, Translational Breast Radiobiology, Institute of Cancer Research, Honorary Consultant Clinical Oncologist (Breast), The Royal Marsden, United Kingdom
  392. Nele Laudus, Biomedical Quality Assurance Research Unit, KU Leuven, Leuven, Belgium
  393. Nicolas Sirtaine, Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  394. Nicole Bussola – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  395. Nicole Burchardi, German Breast Group GmbH, Germany
  396. Nikitina Vlada, Pathology, Krasnoyarsk State MEDICAL UNIVERSITY, Russia
  397. Nils Ternes, Service de Biostatistique et d’Epidémiologie, Gustave Roussy, CESP, Université-Paris Sud, Université Paris-Saclay, Villejuif, France
  398. Nina Radosevic-Robin, Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France
  399. Nobuhiro Shibata, Breast Surgery, Kansai Medical University Hospital, Osaka, Japan
  400. NoriyukiSaito – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  401. Nuh Hatipoglu – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  402. Ogugua Ajemba, Anatomic Pathology, Q2 Solutions, USA
  403. Oleg Gluz, Johanniter GmbH – Evangelisches Krankenhaus Bethesda Mönchengladbach, West German Study Group, Mönchengladbach, Germany
  404. Oliver Grimm, Pathology and Tissue Analytics, Roche
  405. Oluwole Fadare, Division of Anatomic Pathology, University of California San Diego Health System, USA
  406. Ovidiu Preda, Surgical Pathology, San Cecilio Hospital, Granada, Spain
  407. Paola Landini – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org Argentina
  408. Paola Mercurio, Anatomic Pathology, ASST Bergamo Ovest, Italy
  409. Paola Migliora – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  410. Paolo Nuciforo, Molecular Oncology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
  411. Pascal Valerie – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  412. Paul Jank, Department of Pathology, University of Marburg, Marburg, Germany
  413. Paula Gonzalez Ericsson, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee , USA
  414. Paulo Figueiredo – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  415. Paulo Luz, Medical Oncology, Centro Hospitalar Universitario do Algarve, Faro, Portugal
  416. Pawan Kirtani, Department of Histopathology, Manipal Hospitals Dwarka, New Delhi, India
  417. Peggy Adam, Jules Bordet Institute, Belgium
  418. Petar Jelinic, Merck & Co., Inc., Kenilworth, USA
  419. Peter Regitnig – Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
  420. Peter Savas, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia
  421. Peter Vermeulen, Medical Oncology, GZA, Antwerp, Belgium
  422. Peter H. Watson, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
  423. Philippe Aftimos – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org Belgium
  424. Pia Waldenback – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  425. Pieter Westenend – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  426. Polina Dimitrova, Department of Pathology, University Hospital, Bulgary
  427. Pooja Vaid – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  428. Popi Siziopikou, Department of Pathology, Breast Pathology Section, Northwestern University, Chicago, USA
  429. PrayuthRojpornpradit – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  430. Perna Guleria, Army Hospital Research and Referral, Delhi Cantt, New Delhi, India
  431. Priyanka Sharma – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  432. Prudence A. Francis, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
  433. Raffaele Miele, ASL Napoli 1 Centro, Ospedale Pellegrini, Italy
  434. Raj Mohan, Command Hospital, India
  435. Rajendra Singh, Icahn School of Medicine at Mt. Sinai, New York, NY, USA
  436. RamonaErber – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  437. Rashi Gupta – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  438. Rashida Soni, Pathology, Q2 lab solutions and Henry Mayo Newhall Hospital, USA
  439. Rashindrie Perera, University of Melbourne, Australia
  440. Ravi Mehrotra – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  441. Rebecca Dent, Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  442. Reena Merard, Anatomic Pathology, Q2 Lab Solutions, USA
  443. Reena Rahayu, Department of Pathology and Diagnostic Laboratory Services, UKM Medical Centre, Kuala Lumpur, Malaysia
  444. Reena Ramsaroop – Surgical Pathologist, North Shore Hospital, WDHB, Auckland, New Zealand
  445. Remi Picot – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org France
  446. Rena Feinman – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  447. Renan Andrade Pereira, Blazar SAS, Paris, France
  448. Ricardo Preda, Anatomical Pathology, NSW Health, Australia
  449. Richard Huang, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA               
  450. Rick Baehner, Genomic Health
  451. Rin Yamaguchi, Department of Pathology & Laboratory Medicine, Kurume University Medical Center, Fukuoka, Japan.
  452. Robert Mutter, Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
  453. robert wightman             To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  454. Robert Hills         Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, UK                United Kingdom
  455. Robert H. Pierce     Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, USA               USA
  456. Roberto Leon-Ferre Department of Oncology, Mayo Clinic, Rochester, USA          USA
  457. Rocco Cappellesso         Pathological Anatomy, Padova University Hospital Italy
  458. Roland de Wind Department of Pathology, Institut Jules Bordet, Brussels, Belgium    Belgium
  459. Ronald Luff, Anatomic Pathology for Clinical Trials, Quest Diagnostics, USA
  460. Rongshan Yu – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  461. Rosalia Caballero, GEICAM, Spain
  462. Ruben Cuesta – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  463. Ruohong Shui, Department of Pathology, Fudan University Cancer Center, China
  464. Sabine Declercq, Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium
  465. Sabine Linn, Netherlands Cancer Institute, The Netherlands
  466. Saed Sadeghi – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  467. Sam Leung, University of British Columbia, Vancouver, British Columbia, Canada
  468. Sami Tabbarah, Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
  469. Samy Stefan, Teoran Pathology, SCJUPBT, Romania
  470. Sandra Sarancone – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  471. Sandra Souza, Oncology Merck & Co, New Jersey, USA
  472. Sandra O’Toole, The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Australian Clinical Labs, Australia
  473. Sandra Swain, Georgetown University Medical Center, Washington DC, USA
  474. Sangeeta Desai, Pathology, Tata Memorial Centre, India
  475. Sarah Dudgeon, FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, USA
  476. Scooter Willis, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD, USA
  477. Scott Ely, Translational Medicine, Bristol-Myers Squibb, Princeton, USA
  478. Sean Hall, The Gillies McIndoe Research Institute, Wellington, New Zealand
  479. Seher Yuksel – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  480. Seong-Rim Kim, National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, USA
  481. Shahinaz Bedri, Anatomic Pathology, Boston, Massachusetts, USA
  482. Sheeba Irshad, Guy’s Hospital, London, UK; King’s College London, London, United Kingdom
  483. Shigehira Saji, Medical Oncology, Fukushima Medical University Hospital, Japan
  484. Shi-Wei Liu, Sichuan Cancer Hospital, Chengdu, China
  485. Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
  486. Shona Hendry, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
  487. Shyam Kalavar – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  488. Sidar Bagbudar – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  489. Simon Palfreeman – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  490. Simonetta Bianchi, Dipartimento di Scienze della Salute (DSS), Firenze, Italy
  491. Sneha Sant, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia
  492. Sofia Tenorio – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  493. Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, Pennsylvania, USA
  494. Sophia Turner, Patient advocate
  495. Sophie Van den Broek – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  496. Stephan Wienert, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany
  497. Stephen Naber, Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, USA
  498. Stephen B. Fox, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
  499. Stephen J. Luen, Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
  500. Steve Liu, Pathology, Washington University at St. Louis, USA
  501. Stuart Schnitt, Department of Pathology, Brigham and Women’s Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA, USA
  502. Sumana Dey, NCI
  503. Sundry DurÇ­n – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  504. Sunil R. Lakhani, The University of Queensland Centre for Clinical Research and Pathology Queensland, Brisbane, Australia
  505. Susan Fineberg, Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA
  506. Susan Park – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  507. Takahiro Kogawa, Japanese Foundation for Cancer Research, Tokyo, Japan
  508. Takashi Sakatani, Department of Diagnostic Pathology, Nippon Medical School Hospital, Tokyo, Japan               
  509. Takeru Okamoto, Chugai Pharmaceutical Co., Ltd, Japan
  510. Takuya Moriya, Department of Pathology, Kawasaki Medical School, Okayama, Japan
  511. Talia Fuchs, NSW Health Pathology, Sydney, Australia
  512. Tatsuki Kataoka, Department of Diagnostic Pathology, Kyoto University, Kyoto, Japan.
  513. Tatsunori Shimoi , National Cancer Center Hospital, Tokyo, Japan
  514. Teresa Soler, Department of Pathology, University Hospital of Bellvitge, Oncobell, IDIBELL, L’Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain
  515. Tessa Steenbruggen, Medical Oncology, The Netherland Cancer Institute, The Netherlands
  516. Tetsuo Hamada, Department of Surgical Pathology, JR Kyushu Hospital, Kitakyushu, Fukuoka, Japan
  517. Thiago Apolinario, Department of Oncology, IMIP, Brazil
  518. Thomas Gevaert, Department of Development and Regeneration, Laboratory of Experimental Urology, KU Leuven, Leuven, Belgium
  519. Tim Mandelkow – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  520. Timothy d’Alfons, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  521. Timothy Onyuma, Kenyatta National Hospital in Nairobi, Kenya.
  522. Tina Gruosso, Translational Research,  Forbius, Montreal, Canada
  523. Toby Ellis – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  524. Tom John, Department of Medical Oncology, Austin Health, Heidelberg, Australia
  525. Tomohagu Sugie, Department of Surgery, Kansai Medical School, Hirakata, Japan
  526. Tomoharu Sugie, Breast Surgery, Kansai Medical University Hospital, Osaka, Japan.
  527. Tony Kwon – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  528. Toru Mukohara, National Cancer Center Hospital, Tokyo, Japan
  529. Tricia Saurine, Anatomical pathology, Royal North Shore Hospital, Australia
  530. Tsuyoshi Okamoto, Kyowa Kirin Co., Ltd, Japan
  531. Uday, Kurkure, Roche Tissue Diagnostics, Digital Pathology, Santa Clara, CA, USA
  532. Valdivieso, Almeida – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  533. Valentina Hoyos- To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  534. Vasiliki Zolota – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  535. Veerle Bossuyt – Department of Pathology, Massachusetts General Hospital, USA
  536. Veronica Bautista, Department of Pathology, Breast Cancer Center FUCAM, Mexico City, Mexico
  537. Vincent Cockenpot, Department of Pathology, Léon Bérard Cancer Center, Lyon, France
  538. Vincent Engelen – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  539. Vincent Laborie, Pathology, AMAPATH, France
  540. Vincente Peg, Cámaea Pathology Department, H.U. Vall d’Hebron, Barcelona, Spain
  541. Weida Tong, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, US
  542. Weijie Chen, Division of Imaging, Diagnostics, and Software Reliability (DIDSR), Office of Science and Engineering Laboratories (OSEL), Center for Devices and Radiological Health (CDRH), Rockville, USA
  543. Weijie Zhang – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  544. Wentao Yang, Department of Pathology, Fudan University Cancer Center, China
  545. Wenxian Yang, Aginome Scientific Pte Ltd., Xiamen, China
  546. Wilhermo Torres, Pathology, Diagnose, Brazil
  547. William Gallagher – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  548. William Tran, Department of Radiation Oncology, University of Toronto, Toronto, Canada     
  549. Yannick Waumans, Histogenex    
  550. Yara Abdou – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  551. Yazaki Shu, National Cancer Center Hospital, Tokyo, Japan
  552. Yihong Wang, Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Providence, USA
  553. Yinyin Yuan, Centre for Evolution and Cancer; Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
  554. YongjunCha – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  555. Yuan Li – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  556. Yuchun Lin – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  557. Yuichiro Kikawa, Breast Surgery, Kansai Medical University Hospital, Osaka, Japan.
  558. Yuji Kozuka, Department of Pathology, Mie University School of Medicine, Mie, Japan
  559. Yuri Kimura – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  560. Zaheed Husain, Praava Health, Dhaka, Bangladesh
  561. Zheng Yuan, Histogenex, China
  562. Zsuzsanna Bago-Horvath, Department of Pathology, Medical University of Vienna, Vienna, Austria
  563. Zuzana Kos, Department of Pathology, BC Cancer Agency Vancouver Centre, Department of Pathology, Canada
*Update in progress. Please email roberto@salgado.be for any changes.